India’s pharma sector champions quality, innovation

Visakhapatnam: Focusing on ‘Enhancing Pharmaceutical Quality Assurance through good manufacturing practices (GMP)’, a national conference was held at Andhra Pradesh MedTech Zone (AMTZ) here on Wednesday. Organised by the PHD Chamber of Commerce and Industry (PHDCCI) in collaboration with the Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers and AMTZ, the platform brought policymakers, industry leaders, and regulators together.

The critical role of GMP in ensuring safe, effective, and high-quality pharmaceutical products was emphasised on the occasion. The conference underscored that GMP is not merely a regulatory requirement but a comprehensive framework ensuring product quality, safety, and efficacy. Industry leaders highlighted how standardisation, meticulous documentation and robust quality control can mitigate risks like contamination and defects. In today’s competitive business landscape, attracting investments is crucial for companies looking to expand their operations, improve their products, and increase their market share. One factor that can make or break an investment deal is good manufacturing practices (GMP).

Hence, adoption of GMP attracts more investors, the speakers underlined. Nasir Jamal, director, PHDCCI, stated, “Good Manufacturing Practices are foundational for ensuring the production of high-quality, safe, and effective pharmaceutical products.”

Speaking about the evolution of AMTZ, Jitendra Sharma, managing director and CEO, AMTZ, mentioned, “AMTZ aims to bridge science and business for societal good. With initiatives like the GMP-focused certification and validation ecosystem, we aim to empower industries to align certification, regulation and production seamlessly.” A series of insightful sessions formed a part of the event.

  • Related Posts

    DCGI Cracks Down On 90 Unapproved Fixed-Dose Combinations: Cough Syrups, Vitamins, Diabetes Drugs Among Those Flagged For Sale Without Central Approval

    New Delhi — India’s top drug regulator has issued a nationwide alert over 90 fixed-dose combination (FDC) drugs being manufactured and sold without mandatory central approval, directing all state and…

    India’s drug body flags 90 unapproved FDC medicines, states told to take action

    The Central Drugs Standard Control Organisation (CDSCO), India’s top drug regulator, has identified at least 90 unapproved fixed-dose combination (FDC) medicines in circulation and asked states to move against those…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    DCGI Cracks Down On 90 Unapproved Fixed-Dose Combinations: Cough Syrups, Vitamins, Diabetes Drugs Among Those Flagged For Sale Without Central Approval

    DCGI Cracks Down On 90 Unapproved Fixed-Dose Combinations: Cough Syrups, Vitamins, Diabetes Drugs Among Those Flagged For Sale Without Central Approval

    India’s drug body flags 90 unapproved FDC medicines, states told to take action

    India’s drug body flags 90 unapproved FDC medicines, states told to take action

    India advancing as a global hub of affordable, quality healthcare solutions: Dr Jitendra Singh

    India advancing as a global hub of affordable, quality healthcare solutions: Dr Jitendra Singh

    Unapproved drops for dry eyes pose risks: Govt

    Unapproved drops for dry eyes pose risks: Govt

    Semaglutide Patent Expires: Will Diabetes, Weight-Loss Treatment Become More Accessible For Patients?

    Semaglutide Patent Expires: Will Diabetes, Weight-Loss Treatment Become More Accessible For Patients?

    Inaugural Conference of ‘Critical Nephrology Society of India’ (CNSI) puts Best Foot Forward

    Inaugural Conference of ‘Critical Nephrology Society of India’ (CNSI) puts Best Foot Forward